Sugi Predict

Sugi Predict / Compounds / SCHEMBL4985685

SCHEMBL4985685

SCHEMBL4985685

CS(=O)(=O)N1CCN(c2ccc(C(N)=O)cc2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.59
▸ MEN1 O00255 3/20 0.59
▸ KMT2A Q03164 3/20 0.59
▸ SMN1; SMN2 Q16637 4/20 0.57
▸ NPC1 O15118 3/20 0.57
▸ RAB9A P51151 3/20 0.57
▸ POLB P06746 2/20 0.56
▸ LMNA P02545 1/20 0.55
▸ THRB P10828 1/20 0.55
▸ KDM4E B2RXH2 3/20 0.54
▸ GAA P10253 2/20 0.53
▸ CHRNA7 P36544 1/20 0.52
▸ CHRNA10 Q9GZZ6 1/20 0.52
▸ CHRNA9 Q9UGM1 1/20 0.52
▸ ALDH1A1 P00352 2/20 0.50
▸ CHEK1 O14757 1/20 0.49
▸ GLA P06280 1/20 0.48
▸ TSHR P16473 1/20 0.48
▸ GPR119 Q8TDV5 1/20 0.48
▸ F2 P00734 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4990283 0.86 CHRNA7 (0.58) MAPTMEN1KMT2APOLBLMNA
SCHEMBL10901316 0.85 MAPT (0.62) MAPTMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL1482192 0.85 MAPT (0.60) MAPTMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL4991662 0.84 MEN1 (0.66) MAPTMEN1KMT2ASMN1; SMN2POLB
SCHEMBL4994057 0.83 NAMPT (0.53) MAPTMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL12933009 0.81 MAPT (0.67) MAPTMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL13535058 0.81 MAPT (0.67) MAPTMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL4994060 0.81 CHRNA7 (0.53) MEN1KMT2ASMN1; SMN2POLBLMNA
SCHEMBL1397464 0.80 CHEK1 (0.69) MAPTKMT2ASMN1; SMN2NPC1RAB9A
SCHEMBL6152910 0.80 MAPT (0.58) MAPTMEN1KMT2ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007097697-A1 THERAPEUTIC QUINOLINE COMPOUNDS THAT ARE 5HT1B MODULATORS ASTRAZENECA AB (SE) 2007-08-30 — — WO claimed
US-20050182050-A1 Therapeutic heterocyclic compounds ASTRAZENECA AB (SE) 2005-08-18 — — US claimed
US-6812225-B2 PYSCHOLOGICAL DISORDERS; ANTIDEPRESSANTS ASTRAZENECA AB (SE) 2004-11-02 — — US claimed
CN-1131222-C Benzamide derivatives and their use as inhibitors of APOB-100 secretion GLAXO GROUP LTD (GB) 2003-12-17 — — CN claimed
WO-2003047575-A1 THERAPEUTIC BENZAMIDE DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-06-12 — — WO claimed
US-20030013708-A1 Therapeutic heterocyclic compounds ASTRAZENECA AB (SE) 2003-01-16 — — US claimed
EP-1135378-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS GLAXO GROUP LIMITED (GB) 2001-09-26 — — EP claimed
WO-2000032582-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS GLAXO GROUP LIMITED (GB) 2000-06-08 — — WO claimed
WO-2020183011-A1 HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER INSTITUT CURIE (FR) 2020-09-17 — — WO disclosed
US-20080076759-A1 Therapeutic Heterocyclic Compounds 507 ASTRAZENECA AB (SE) 2008-03-27 — — US disclosed
US-7285662-B2 Therapeutic heterocyclic compounds ASTRAZENECA AB (SE) 2007-10-23 — — US disclosed
WO-2007097697-A1 THERAPEUTIC QUINOLINE COMPOUNDS THAT ARE 5HT1B MODULATORS ASTRAZENECA AB (SE) 2007-08-30 — — WO disclosed
US-20060178372-A1 Therapeutic quinoline compounds ASTRAZENECA AB (SE) 2006-08-10 — — US disclosed
US-7045514-B2 Therapeutic heterocyclic compounds ASTRAZENECA AB (SE) 2006-05-16 — — US disclosed
WO-2002055012-A2 THERAPEUTIC HETEROCYCLIC COMPOUNDS ASTRAZENECA AB (SE) 2002-07-18 — — WO disclosed
WO-2002055013-A2 THERAPEUTIC CHROMONE COMPOUNDS ASTRAZENECA AB (SE) 2002-07-18 — — WO disclosed
WO-2002055014-A2 THERAPEUTIC CHROMAN COMPOUNDS ASTRAZENECA AB (SE) 2002-07-18 — — WO disclosed
WO-2001097810-A2 USE OF THERAPEUTIC BENZAMIDE DERIVATIVES GLAXO GROUP LIMITED (GB) 2001-12-27 — — WO disclosed
EP-1135378-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS GLAXO GROUP LIMITED (GB) 2001-09-26 — — EP disclosed
WO-2000032582-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS GLAXO GROUP LIMITED (GB) 2000-06-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076759-A1 Therapeutic Heterocyclic Compounds 507 HTR1A, HTR1B, HTR1D MAPT 698/4885MEN1 382/4885KMT2A 2073/4885
US-20060178372-A1 Therapeutic quinoline compounds HTR1B, HTR3B, HTR1A MAPT 628/4885MEN1 192/4885KMT2A 910/4885
US-20050182050-A1 Therapeutic heterocyclic compounds HTR1B, HTR1D, HTR1A MAPT 653/4885MEN1 285/4885KMT2A 1315/4885
US-20030013708-A1 Therapeutic heterocyclic compounds HTR1A, HTR1D, HTR1B MAPT 661/4885MEN1 215/4885KMT2A 1265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.